Shots:

• The FDA’s BT and EMA’s PRIME designations are based on data from the P-I MajesTEC-1 study evaluating the safety and efficacy of teclistamab (Ab targeting BCMA and CD3) in adults with r/rMM. The findings will be presented at ASCO 2021
• In preclinical studies- the therapy kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients
• The company is also evaluating the therapy in a P-II clinical study for r/MM and also in combination studies. The EMA has granted PRIME designations for Teclistamab in Jan’2021

  Ref: PR Newswire | Image: Janssen